Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × ulixertinib × Clear all

Phase

Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1

Status

Terminated 3 Active not recruiting 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Histiocytic Neoplasms 1

Interventions

pembrolizumab 198 Carboplatin 181 Cisplatin 166 Specimen Handling 164 Magnetic Resonance Spectroscopy 140 Radiotherapy 122 Bevacizumab 116 Gemcitabine 108 Cyclophosphamide 105 Drug Therapy 103 Capecitabine 95 Paclitaxel 93 Nivolumab 93 venetoclax 90 Biopsy 83 Oxaliplatin 81 tislelizumab 69 durvalumab 69 Rituximab 66 Docetaxel 59 atezolizumab 58 Fluorouracil 58 Etoposide 58 Radiosurgery 57 toripalimab 56 Pemetrexed 56 Dexamethasone 54 lenvatinib 52 Azacitidine 52 130-nm albumin-bound paclitaxel 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06411821 2025-12-15

Ulixertinib in People With Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting

Histiocytic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡